Business
BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937
BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means o...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Oct. 31, 2018\n\n\n\n- New Patent Extends BLU-5937's Patent Protection to 2038 -\n- Expands Portfolio That Also Includes Patent Protection for Composition of Matter for BLU-5937 in All Major Pharmaceutical Markets - \n LAVAL, QC, Oct. 31, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) (\"BELLUS Health\" or the \"Company\"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that the U.S. Patent and Trademark Office has issued U.S Patent No. 10,111,883, granting claims for the use of BELLUS Health's lead drug candidate BLU-5937 for the treatment of chronic cough without affecting taste response. More generally, the patent entitled \"Selective P2X3 Modulators\" claims the use of imidazopyridine compounds that are selective for the P2X3 receptor as a means of minimizing taste perturbation in patients treated for chronic cough. In addition to BLU-5937, the patent claims the use of related selective imidazopyridine compounds and pharmaceutical compositions comprising BLU-5937. Patent No. 10,111,883 has an expiration date of 2038, excluding any potential patent term extension. \nThis patent adds to BLU-5937's intellectual property portfolio which already includes composition of matter patent protection for BLU-5937 in all major pharmaceutical markets (U.S., Europe, Japan and China) until 2034. \n\"In multiple clinical trials, treating with a P2X3 antagonist was shown to be highly efficacious in the treatment of chronic cough\" said Roberto Bellini, President and CEO of BELLUS Health. \"However, this anti-tussive efficacy comes coupled with a profound effect on taste perception, including taste loss, due to poor selectivity for the P2X3 receptor. This new U.S. patent affords a broad and comprehensive protection for our...